Kornimate/medical-research-clean huggingface dataset:
effect of postoperative prolonged sedation with dexmedetomidine after successful reperfusion with evt on long-term prognosis in patients with ais (ppdet)

Conditions: Acute Ischemic Stroke

Summary: dexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury. the investigators hypothesized that the prolonged sedation of dexmedetomidine after successful reperfusion of endovascular thrombectomy may improve the clinical outcome of acute ischemic stroke patients.

endovascular treatment with mechanical thrombectomy is the standard treatment for acute large vessel occlusion. dexmedetomidine is a commonly used sedative in endovascular thrombectomy of acute ischemic stroke. dexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury. the investigators hypothesized that the prolonged sedation of dexmedetomidine after successful reperfusion of endovascular thrombectomy may improve the clinical outcome of acute ischemic stroke patients.

Eligibility criteria:
inclusion criteria: * 2≤nihss≤25 * mrs score before stroke was less than 3 * acute ischemic stroke (including anterior circulation) * mtici rate 2b or 3 * according to the 2018 aha/asa guidelines for the management of acute ischemic stroke, patients who plan to receive mechanical thrombectomy under local anesthesia and sedation * informed consent was signed by patient or legal representative exclusion criteria: * intracerebral hemorrhage occurred in the responsible vessel area in the past 6 weeks * patients who had received stent treatment at the responsible vessel in the past * neurological function was restored at or before angiography * patients who are allergic to heparin, aspirin, clopidogrel, rapamycin, lactic acid polymer, poly (n-butyl methacrylate), stainless steel, anesthetics and contrast agents or have contraindications * hemoglobin was less than 70g/l, platelet count was less than 50×109/l, international normalized ratio (inr) greater than 1.5 (irreversible), there are uncorrectable bleeding factors * blood glucose \ 22.2 mmol/l * severe liver or kidney disfunction, alt\>3 times the upper limit of normal value or ast\>3 times the upper limit of normal value, creatinine\>1.5 times the upper limit of normal value * pregnant or lactating women * previous history of mental illness * stroke with other acute diseases or postoperative stroke of other operation * heart rate less than 50bpm, second or third degree of atrioventricular block (except for pacemaker implantation), systolic blood pressure less than 90mmhg (two vasoactive drugs were already infused continuously )

Keywords: endovascular thrombectomy dexmedetomidine modified rankin scale
a phase 1b/2 study of rebastinib (dcc-2036) in combination with paclitaxel in patients with advanced or metastatic solid tumors

Conditions: Locally Advanced or Metastatic Solid Tumor

Summary: this is an open-label phase 1b/2 multicenter study of rebastinib (dcc-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (pk) in patients with advanced or metastatic solid tumors.


Eligibility criteria:
inclusion criteria: 1. male or female patients ≥18 years of age at the time of informed consent 2. part 1 histologically confirmed diagnosis of a locally advanced or metastatic solid tumor for which paclitaxel is considered appropriate treatment 3. part 2 * triple-negative and stage iv inflammatory breast cancer * recurrent ovarian cancer * recurrent, metastatic or high-risk endometrial cancer * advanced (stage iii or iv), or recurrent gynecological carcinosarcoma * homologous or heterologous type carcinosarcoma (malignant mixed mullerian tumor \[mmmt\] allowed 4. eastern cooperative oncology group performance status (ecog ps) of ≤2 5. able to provide an archival tumor tissue sample 6. adequate organ function and bone marrow reserve 7. if a female of childbearing potential, must have a negative pregnancy test prior to enrollment 8. patient must provide signed consent to participate in the study and is willing to comply with study-specific procedures exclusion criteria: 1. received prior anticancer or other investigational therapy within 28 days or 5× the half-life prior to the first dose 2. not recovered from prior-treatment toxicities to grade ≤1 3. peripheral neuropathy of any etiology \>grade 1 4. concurrent malignancy 5. known active central nervous system (cns) metastases 6. use of systemic corticosteroids 7. known retinal neovascularization, macular edema or macular degeneration 8. history or presence of clinically relevant cardiovascular abnormalities 9. qt interval corrected by fridericia's formula (qtcf) \>450 ms in males or \>470 ms in females 10. left ventricular ejection fraction (lvef) \<50% at screening 11. arterial thrombotic or embolic events 12. venous thrombotic event 13. active infection ≥grade 3 14. human immunodeficiency virus (hiv) or hepatitis c (hcv) infection only if taking medications excluded per protocol, active hepatitis b (hbv), or active hcv infection 15. use of proton pump inhibitors 16. if female, the patient is pregnant or lactating 17. major surgery 4 weeks prior to the first dose of study drug 18. malabsorption syndrome or other illness which could affect oral absorption 19. known allergy or hypersensitivity to any component of rebastinib or any of its excipients. 20. any other clinically significant comorbidities

Keywords: rebastinib paclitaxel breast cancer ovarian cancer endometrial cancer gynecological carcinosarcoma malignant mixed mullerian tumor (mmmt)
surgery with or without chemotherapy in treating patients with stage ii or stage iii cancer of the esophagus

Conditions: Esophageal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. it is not known whether chemotherapy before surgery is more effective than surgery alone in treating cancer of the esophagus. purpose: randomized phase iii trial to compare the effectiveness of surgery with or without chemotherapy in treating patients with stage ii or stage iii cancer of the esophagus.

objectives: i. compare resectability and survival in patients with stage ii/iii esophageal cancer treated with neoadjuvant cisplatin/fluorouracil vs. surgery alone. outline: this is a randomized study. patients are randomized to one of two groups. the first group receives cisplatin and fluorouracil every 4 weeks for 3 courses followed by esophagectomy and regional lymphadenectomy. the second group undergoes esophagectomy and regional lymphadenectomy alone. all patients are followed for survival. projected accrual: a total of 240 patients will be entered over 4 years.

Eligibility criteria:
disease characteristics: histologically confirmed esophageal squamous cell cancer that is stage t2-3 nx m0 patient characteristics: age: 18 to 75 performance status: who 0-2 hematopoietic: not specified hepatic: not specified renal: not specified other: no second malignancy within 5 years except: basal cell skin carcinoma carcinoma in situ of the cervix prior concurrent therapy: no prior chemotherapy or radiotherapy

Keywords: stage ii esophageal cancer stage iii esophageal cancer squamous cell carcinoma of the esophagus
myfortic® for minimal change nephrotic syndrome (mcns): a randomized study

Conditions: Nephrosis, Lipoid

Summary: study objective: to investigate the potential therapeutic efficacy of enteric-coated mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for minimal change nephrotic syndrome (mcns).

this is a prospective, open-label, randomized study in which patients who present for the first time with a clinical diagnosis of idiopathic mcns proven on renal biopsy will be assigned to either conventional standard-dose prednisolone monotherapy or myfortic combined with low-dose prednisolone treatment for 6 months. clinical response and relapse rates within 6 months of treatment cessation will be the main outcome parameters.

Eligibility criteria:
inclusion criteria: * male or female 18 - 65 years of age * first histologic diagnosis of mcns * proteinuria \> 3.5 g/day * patients who are willing to give written, informed consent exclusion criteria: * presence of secondary causes of mcns * history of glomerular disease including mcns * egfr \< 50 ml/min/1.73m2 * renal histology showing pathologies other than mcns * female of child-bearing age who are unwilling to practice effective contraception * patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study

Keywords: minimal change nephrotic syndrome corticosteroid mycophenolate remission safety
a six month, safety follow-up study in eosinophilic esophagitis subjects who completed study pr-021

Conditions: Eosinophilic Esophagitis

Summary: this purpose of this study is the long-term follow-up of glucocorticosteroid-related adverse events and hypothalamic-pituitary-adrenal axis (hpa) suppression in subjects after discontinuation of study drug received in the pr-021 study (safety and tolerability study of oral eur-1100 to treat eosinophilic esophagitis). the study will also provide the opportunity to better understand the natural course of eosinophilic esophagitis and define the treatment modalities of eosinophilic esophagitis with eur-1100, such as the need for chronic maintenance or intermittent treatment. all subjects who complete pr-021 will be offered the opportunity to participate in this study. the duration of this follow-up study is six months, during which subjects will visit the clinic for safety evaluation and clinical symptom assessment at the screening, week 8, week 16, and week 24 visits. additional phone visits will occur at week 4, week 12, and week 20.


Eligibility criteria:
inclusion criteria: * subject completed full participation in study pr-021 (subjects discontinued prematurely from pr-021 due to hpa axis suppression will be eligible for study pr-022) * written informed consent (parent or legal guardian must sign when applicable) and assent form, if required * willing and able to adhere to all study procedures exclusion criteria: * subjects already requiring medications or procedures for the treatment of eoe at the time of enrollment into the follow-up study, such as systemic (oral or parenteral) or inhaled corticosteroids, esophageal dilation, proton pump inhibitors (ppis) and/or dietary restrictions; in the case of subjects already on ppis and /or dietary restrictions during study pr-021, only subjects requiring an increase in dosage of ppis and/or new dietary restrictions because of worsening of symptoms will be excluded * any physical, mental, or social condition, history or concurrent illness or laboratory abnormality that, in the investigator's judgment, might interfere with study procedures or the ability of the subject to adhere to and complete the study * contraindication to esophagogastroduodenoscopy (egd) or esophageal biopsy or narrowing of the esophagus precluding egd * female subjects who are pregnant or breastfeeding * participation in a clinical study involving an investigational drug or investigational device
evaluation of 18f-dopa and 123i-mibg uptake in the patients with neuroblastoma

Conditions: Neuroblastoma

Summary: neuroblastic tumors are childhood neoplasms that possess amino acid decarboxylase (aadc) activity and meta-iodobenzylguanidine(mibg), they can theoretically be imaged by (18)f-fluorodihydroxyphenylalanine ((18)f-fdopa) and (123)i-meta-iodobenzylguanidine((123)i-mibg) pet, they are new and specific diagnostic and follow-up tools for neuroendocrine tumors. in this study, we explored the accuracy and clinical role of (18)f-fdopa and (123)i-mibg pet in neuroblastic tumors. methods: patients with tissue-proven neuroblastic tumors receiving (18)f-fdopa pet or (123)i-mibg at initial diagnosis or during follow-ups were enrolled. the sensitivity and specificity of (18)f-fdopa or (123)i-mibg pet were compared to each other and compared to(18)f-fdg pet, using tumor histology as the standard.


Eligibility criteria:
inclusion criteria: * (1) diagnosed by clinical criteria(one of below) 1. proved as neuroblastoma by a pathological section 2. bone meta with 24 hrs urine vma(vanillylmandelic acid )or hva (homovanillic acid) elevated 3. ct or mri found tumor around adrenal gland or neuroblastic tumor * (2) age between 0-30 years old，body weight over 2.5kg * (3) signed inform consent form exclusion criteria: * (1)ast and alt \> 200u/l、cre \> 2.5mg/dl * (2)allerg to 18f-dopa、123i-mibg * (3)subject not fit this study(assessed by pi) * (4)no more need to arrenge pet because disease progress, assessed by vs
plasma glycosaminoglycans as diagnostic and prognostic biomarkers in surgically treated renal cell carcinoma

Conditions: Renal Cell Carcinoma

Summary: in this study, the investigators profiled plasma glycosaminoglycans (gags) in a retrospective consecutive series of patients with a radiographic finding of renal mass referred to primary surgery for renal cell carcinoma (rcc). a control group was formed by measuring plasma gags in healthy volunteers. the primary endpoints were the specificity and sensitivity of plasma gags in the detection of early stage rcc in pre-surgical samples versus healthy individuals. the investigators further analyzed how plasma gags varied according to stage, grade, rcc histology, other renal masses, and after surgery. finally, the investigators estimated whether plasma gags could be used for prediction and surveillance of rcc recurrence.


Eligibility criteria:
inclusion criteria: * patients with radiographic finding of renal mass referred to primary surgery; * healthy volunteers without any history of malignancy. exclusion criteria: * no records on date of surgery; * a pre-operative sample was obtained 50 days or earlier with respect to the date of surgery; - absence of pre-operative samples following filtering out outliers or laboratory assay failures.

Keywords: glycosaminoglycans biomarkers diagnostics prognostic liquid biopsy
the effect of different sensory conditions on sensory interaction in balance

Conditions: Balance Assessment; Sensory Science

Summary: the ability of humans to maintain spatial orientation and balance control relies on accurate and complete sensory information. this study aims to investigate the effects of different sensory conditions on the sway index (balance). adults with normal hearing, vision, and balance abilities will perform the modified clinical test of sensory interaction on balance (mctsib), a test from the biodex balance system, under varying sensory conditions. the first sensory condition involves situations where the cursor indicating the individual's center of gravity on the device is either visible or hidden. the second condition examines whether the eyes-closed state during the test is achieved through voluntary eye closure or by external equipment (e.g., goggles or eye patches). the values obtained will allow comparisons of the effects of different sensory conditions on the sway index. the study will be conducted between january 2025 and march 2025 at the bezmialem vakıf university cardiac physiotherapy and rehabilitation education and research laboratory with healthy young adults. participants will be selected voluntarily, and the assessments will be conducted in compliance with the guidelines of the declaration of helsinki.


Eligibility criteria:
inclusion criteria: * being between the ages of 18 and 45. * providing informed consent to participate in the study after receiving detailed information about the research. exclusion criteria: * having visual or hearing impairments. * presence of musculoskeletal, neurological, or orthopaedic conditions (e.g., lower extremity alignment disorders, excessive anteversion, severe pes planus) that could affect the study results. * having mental or physical problems severe enough to impair communication. * participation in any rehabilitation program within the past six months.

Keywords: balance assessment sensory condition
safety study of an oral vaccine to prevent seasonal influenza

Conditions: Influenza

Summary: the purpose of this study was to demonstrate the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza. the study was a placebo controlled, double blinded trial at a single site. the study was conducted under two separate protocols. initially single administrations at two dose levels (low dose and mid dose) of the oral vaccine was tested in a placebo controlled study (37 subjects). and subsequently a single high dose of the oral vaccine was tested in a separate placebo-controlled study (24 subjects).

low and mid dose study was conducted under protocol number vxa02-001 high dose study was conducted under protocol number vxa02-003

Eligibility criteria:
inclusion criteria: * in good health as established by medical history, physical examination, and laboratory testing at the time of enrollment. exclusion criteria: * positive for h1 influenza by hai. * has had an influenza vaccine in the past 2 years. * current history of chronic alcohol consumption and/or illicit and/or recreational drug use. * history of any confirmed or suspected immunodeficient or immunosuppressive condition * positive serology for hiv, hcv, or hbv * previous serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain. * history of irritable bowel disease or other inflammatory digestive or gastrointestinal conditions that could affect the intended distribution of the vaccine targeting the mucosa of the small intestine * use of proton pump inhibitors(nexium, prilosec). * stool sample with occult blood at baseline exam

Keywords: influenza h1n1 flu seasonal
determining the microbiota composition of the middle meatus in parkinson's

Conditions: Parkinson Disease

Summary: the exact cause of pd remains unknown, but current theories suggest that it results from a combination of hereditary or genetic factors (i.e. family traits ) and exposure to unknown substances in the environment. the purpose of this study is to investigate whether toxins produced by bacteria that live within the nasal canal (nose) and the intestines of people with pd might have a role in causing the disease. the investigators in this study would like to look at the types of bacteria that live in the nasal canals and intestines of pd subjects and compare them with those of subjects who do not have pd.


Eligibility criteria:
inclusion criteria: - 1. patients with a clinical diagnosis of parkinson's disease by united kingdom parkinson disease society brain bank criteria will be recruited. 2. hoehn \& yahr stage 1-3 3. parkinson's disease symptomatic treatment will be allowed. 4. subjects with deep brain stimulation are allowed. exclusion criteria: * 1. occupation expected to change intestinal flora pattern (e.g. sanitation worker) 2. treatment with medications that may induce parkinsonism (metoclopramide, typical, or atypical antipsychotic agents) 3. treatment within 12 weeks with systemic antibiotics 4. known diagnosis of inflammatory bowel disease 5. symptomatic organic gi disease other than hemorrhoids and hiatal hernia or abdominal surgeries for symptomatic gi disease such as bowel resection, diverticular surgery, colostomy, etc (subjects with a history of an appendectomy or cholesytectomy for benign disease more than 5 years prior to presentation are allowed). 6. symptomatic functional gi disease that significantly impairs intestinal motility such as scleroderma or use of gi motility drugs 7. acute illness requiring immediate hospitalization 8. pre-existent organ failure or comorbidities as these may change gi flora: 1. liver disease (cirrhosis or persistently abnormal ast or alt that are 2x\> normal); 2. kidney disease (creatinine\>2.0 mg/dl); 3. uncontrolled psychiatric illness; 4. clinically important lung disease or heart failure; 5. hiv disease; 6. alcoholism, unreliable drinking history; or consumption of alcohol more than 3 times a week or binge drinking or drinking more than or equal to 3 drinks per occasion; 7. transplant recipients; 8. diabetes; 9. clinically significant dehydration or clinically detectable ascites or peripheral edema or cardiac failure 9. presence of short bowel syndrome or severe malnutrition with ideal body weight \< or = 90% or 10. estimated survival \<1 year and karnofsky performance status \<50%; 11. use of immunosuppressive medications within 3 months of enrollment 12. chronic use of diuretics
the effect of a physical activity program on burnout risk among secondary school teachers

Conditions: Burnout Risk; Physical Activity

Summary: the purpose of this study is to assess the effect of a 6 weeks physical activity program on burnout risk in secondary school teachers. also, the difference between the effects of moderate en vigorous-intensity physical activity will be investigated.

given the increased risk of burnout among secondary school teachers, effective interventions are needed. physical activity may play a big role in preventing and/or reducing burnout. therefore the purpose of this research is to investigate the effect of physical activity on the risk of burnout in secondary school teachers. the participants in the intervention group will be asked to perform a specific physical activity program (including running and/or cycling at a moderate or vigorous intensity) for 6 weeks. the control group will be asked to keep their lifestyle as it was prior to the study. to assess the effect of this activity program, the participants will have to fill in a questionnaire at three time points. lastly, the participants have to fill in an activity diary every day, enabling to assess intervention adherence.

Eligibility criteria:
inclusion criteria: * participants who are not meeting the guidelines for physical activity. * participants who are willing to run or cycle. exclusion criteria: * participants who are not speaking the dutch language. * participants unable or unwilling to give informed consent. * participants who are not able to be physically active, due to injuries, physical disabilities, etc. * participants who already met the guidelines for physical activity. * participants who are following a diet. * participants who have been following psychological treatment in the past 6 months.